Cliff Asness's IMNM Position Overview
Cliff Asness (via Aqr Capital Management LLC) currently holds 18,728 shares of Immunome, Inc. (IMNM) worth $409,582, representing 0.00% of the portfolio. First purchased in 2024-Q1, this short-term holding has been held for 6 quarters.
Based on 13F filings, Cliff Asness has maintained this position in IMNM for several quarters, showing initial confidence in the investment. Largest addition occurred in Q1 2026, adding 18,728 shares. Largest reduction occurred in Q4 2024, reducing 11,703 shares.
Analysis based on 13F filings available since 2013 Q2
Cliff Asness's Immunome (IMNM) Holding Value Over Time
Track share changes against reported price movement
Quarterly Immunome (IMNM) Trades by Cliff Asness
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +18,728 | New Buy | 18,728 | $21.87 |
| Q1 2025 | -10,276 | Sold Out | 0 | $0.00 |
| Q4 2024 | -11,703 | Reduce 53.25% | 10,276 | $10.62 |
| Q3 2024 | +5,915 | Add 36.82% | 21,979 | $14.62 |
| Q2 2024 | +4,129 | Add 34.60% | 16,064 | $12.10 |
| Q1 2024 | +11,935 | New Buy | 11,935 | $24.68 |
Cliff Asness's Immunome Investment FAQs
Cliff Asness first purchased Immunome, Inc. (IMNM) in Q1 2024, acquiring 11,935 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness has held Immunome, Inc. (IMNM) for 6 quarters since Q1 2024.
Cliff Asness's largest addition to Immunome, Inc. (IMNM) was in Q1 2026, adding 18,728 shares worth $409,582.
According to the latest 13F filing for Q1 2026, Cliff Asness's firm, Aqr Capital Management LLC, owns 18,728 shares of Immunome, Inc. (IMNM), valued at approximately $409,582.
As of the Q1 2026 filing, Immunome, Inc. (IMNM) represents approximately 0.00% of Cliff Asness's publicly disclosed stock portfolio, making it one of their key holdings.
Cliff Asness's peak holding in Immunome, Inc. (IMNM) was 21,979 shares, as reported at the end of Q3 2024.